Market Overview

UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside

Related LLY
Eli Lilly Release Confirms FDA Approval If Portrazza
US Stock Futures Edge Higher Ahead Of Jobless Claims Report
Biotechs Weaken, But These Names Have Bullish Charts (Investor's Business Daily)

Citigroup maintained Eli Lilly and Company (NYSE: LLY) with a Buy rating and raised the price target from $55.00 to $60.00.

Citigroup noted, "Lilly's base business is performing ahead of our expectations (Alimta, Elanco, Diabetes and Emerging markets). Consequently, we continue to see upside for Lilly due to the asymmetric risk reward given the minimal value being discounted for the key pipeline agent ramucirumab (cancer). Buy-rated Pfizer, Lilly and Forest remain our favoured names in US pharma."

Eli Lilly closed at $54.32 on Tuesday.

Latest Ratings for LLY

Nov 2015BMO CapitalUpgradesMarket PerformOutperform
Oct 2015Leerink SwannMaintainsOutperform
Oct 2015Credit SuisseUpgradesNeutralOutperform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings


Related Articles (LLY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters